Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DCIR-mediated inhibitory regulation of TLR7-MyD88 axis prevents autoimmune neuroinflammation.

iScience·2026
Same author

Headache prevalence and types in multiple sclerosis and related neuroimmunological diseases: A multicenter study.

Cephalalgia : an international journal of headache·2026
Same author

[Febrile infection-related epilepsy syndrome (FIRES) with the claustrum sign in a 55-year-old woman: a case report].

Rinsho shinkeigaku = Clinical neurology·2026
Same author

Outcomes and disease activity during and after pregnancy in Asian women with MOGAD.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

A multicenter, retrospective study in patients with multiple sclerosis treated with natalizumab in a real-world setting in Japan: The REFIND study.

Multiple sclerosis and related disorders·2026

Related Experiment Video

Updated: May 16, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

[Neuromyelitis optica].

Ichiro Nakashima1

  • 1Department of Neurology, Tohoku University School of Medicine.

Rinsho Shinkeigaku = Clinical Neurology
|December 1, 2012
PubMed
Summary
This summary is machine-generated.

Neuromyelitis optica (NMO) is an autoimmune CNS disorder. Early treatment with steroids and plasmapheresis helps manage relapses, while immunosuppressants are preferred for long-term prevention.

More Related Videos

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

Related Experiment Videos

Last Updated: May 16, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

Area of Science:

  • Neurology
  • Immunology
  • Neuroimmunology

Context:

  • Neuromyelitis optica (NMO) is a severe inflammatory demyelinating disease of the central nervous system.
  • NMO is characterized by recurrent optic neuritis and transverse myelitis.
  • Distinguishing NMO from multiple sclerosis (MS) relies on detecting the anti-aquaporin-4 (AQP4) antibody.

Purpose:

  • To outline the current understanding of Neuromyelitis Optica (NMO) management.
  • To differentiate NMO from other central nervous system demyelinating disorders.
  • To discuss treatment strategies for NMO relapses and prevention.

Summary:

  • Relapse management involves high-dose intravenous methyl-prednisolone, with plasmapheresis for refractory cases.
  • Steroid treatment for relapses includes 1g IV methyl-prednisolone for 3-5 days, followed by oral prednisone.
  • Preventive strategies for NMO primarily utilize immunosuppressive agents, contrasting with immunomodulatory drugs used for MS.
  • While low-dose oral prednisolone shows efficacy in some populations, non-steroidal immunosuppressants are recommended for long-term NMO management to mitigate steroid side effects.

Impact:

  • Early and appropriate treatment can improve recovery from NMO relapses.
  • Distinguishing NMO is crucial for selecting effective therapeutic interventions.
  • The shift towards immunosuppressive agents for prevention aims to reduce long-term steroid toxicity.
  • Understanding NMO pathogenesis and treatment is vital for improving patient outcomes in neuroinflammatory diseases.